Meeting
2022 ASCO Gastrointestinal Cancers Symposium
An open-label phase 2 study of lenvatinib plus pembrolizumab in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001).
Authors
Akihito Kawazoe
National Cancer Center Hospital East, Kashiwa, Japan
Akihito Kawazoe , Masashi Wakabayashi , Hideki Furuya , Akihiro Sato , Naoya Sakamoto , Takeshi Kuwata , Takahiro Kinoshita , Kohei Shitara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04745988
DOI
10.1200/JCO.2022.40.4_suppl.TPS372
Abstract #
TPS372
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).
First Author: Chung-Han Lee
Poster
2020 Gastrointestinal Cancers Symposium
An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).
First Author: Akihito Kawazoe
Poster
2024 ASCO Annual Meeting
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).
First Author: Hui-Chuan Sun
Poster
2024 ASCO Genitourinary Cancers Symposium
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.
First Author: Elshad Hasanov